CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

LIVE MARKETS-Biotech dealmaking keeps adding up

By Reuters News

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

BIOTECH DEALMAKING KEEPS ADDING UP

Biotech stocks have struggled to regain their summer highs, but M&A activity across the sector remains brisk even as quarterly deal flow has fluctuated this year.

The latest example comes from reports that AstraZeneca AZN.L made a non-binding offer for Rhythm Pharmaceuticals RYTM.O last month through its rare-disease unit Alexion. The deal hasn't been confirmed, but the news sent Rhythm shares up 28% and put biotech M&A back in focus.

One of the key drivers behind the deal flow is a looming wave of patent expiries facing large drugmakers, prompting them to fill product pipelines through acquisitions.

Highlighting the logic behind much dealmaking, Jefferies says interest in Rhythm is unsurprising and that its growing revenues "could help offset some of pharma's upcoming LOE's", or losses linked to patent expirations.

BioBucks data show 76 biotech and biopharma deals worth nearly $208 billion have been announced so far this year, up from 49 worth roughly $149 billion at the halfway mark of 2026.

Since June 30, the sector has added 27 deals and nearly $59 billion of disclosed value, even though third-quarter activity slowed from the exceptional pace seen in the second quarter.

The S&P Biotech ETF has fallen about 6% from its August peak, making targets look cheaper, but remains up roughly 30% for the year, comfortably beating the S&P 500 .SPX.

(Danilo Masoni)

EARLIER ON LIVE MARKETS:

FRENCH BOND ANGST COULD BOOST KNOTT'S ECB CANDIDATURE CLICK HERE

CONSUMER STOCKS PUSH STOXX CLOSE TO AUGUST PEAK CLICK HERE

BEFORE THE BELL: ROTATION OUT OF AI ROLLS ON AHEAD OF BOE CLICK HERE

GOLDILOCKS OR GRIDLOCK? CLICK HERE

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.